INNSBRUCK, Austria — September 29, 2026
Cyprumed GmbH announced that MSD has initiated a Phase 1 clinical trial of a proprietary drug candidate formulated using Cyprumed’s licensed oral drug delivery technology, marking the first Cyprumed technology program to enter human clinical development. The milestone follows an existing collaboration between the companies to develop oral formulations of MSD peptides using Cyprumed’s tablet-based delivery platform and triggers a milestone payment to Cyprumed. Under the companies’ Non-Exclusive License and Option Agreement, Cyprumed is eligible to receive up to $493 million in upfront, development, regulatory and net sales milestones associated with products developed through the collaboration. The clinical advancement provides the first human-development test of Cyprumed’s approach to oral peptide delivery.
Cyprumed Platform Targets Oral Peptide Delivery
Cyprumed’s technology is designed to enable oral administration of therapeutic peptides, an area that has historically presented challenges because many peptide medicines have limited absorption when administered through the gastrointestinal tract. The company’s platform uses tablet formulations designed to improve oral bioavailability while addressing practical factors such as food-related effects on drug absorption. Cyprumed said its approach is intended to provide more consistent drug exposure and potentially greater flexibility for patients regarding medication and meals. The technology is being developed for applications including GLP-1 analogues, macrocycles and mini-proteins, with the company focusing on formulations that can potentially provide patient-friendly alternatives to injectable administration. The MSD program will provide the first opportunity to assess the technology in a human clinical setting.
MSD Phase 1 Trial Marks Technology Validation Milestone
The Phase 1 study represents the first Cyprumed technology program to progress into human clinical development, following the companies’ April 2025 collaboration agreement. The trial will evaluate an MSD proprietary drug candidate formulated using Cyprumed’s oral tablet technology. Specific details regarding the candidate and the clinical study were not disclosed in the announcement. Cyprumed said the start of clinical development triggers a contractual milestone payment under the collaboration. The broader agreement gives Cyprumed the potential to receive up to $493 million across specified development, regulatory and net sales milestones. While entry into a Phase 1 study provides an important development milestone, the clinical performance, safety and pharmacokinetic characteristics of the formulation will need to be established through the ongoing human studies.
Advertisement
Oral Tablet Approach Emphasizes Scalability and Manufacturing
Cyprumed said its oral delivery platform is designed to combine peptide bioavailability with a practical and scalable tablet manufacturing approach. The technology relies on well-characterized pharmaceutical excipients, which the company believes can support regulatory development, manufacturing consistency and commercial scalability. By using established excipients and a tablet-based formulation, Cyprumed aims to reduce some of the manufacturing and development complexity associated with emerging oral peptide delivery technologies. The company is positioning its platform as a potential enabling technology for chronic therapies where convenient oral administration could provide an alternative to injectable dosage forms. The initiation of the MSD Phase 1 program provides the first clinical-stage validation opportunity for these formulation principles and could inform the future development of additional peptide-based products using the platform.
Source :Cyprumed press release
